clinical trial · NCT07059650
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Diffuse Large B-Cell LymphomaDZD8586+R-CHOPDZD8586+R-GemOxDZD8586+BR
brief summary
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.
started
Aug 19, 2025
primary completion
Oct 1, 2030
completion
Oct 1, 2030
last updated
Apr 1, 2026
official title
A Phase Ib/II, Multicenter Study to Evaluate the Efficacy and Safety of DZD8586 Combination Therapy in Diffuse Large B-cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol